ABSTRACT
cases, the antimicrobial therapy is unable to eradicate the pseudomads infection. Despite also unclear, there is evidence that the biofilm formation is responsible, in part, for therapeutic failure (6, 7).
Additionally, the biofilm mode of growth makes the bacteria more resistant to antimicrobial agents due to: 1) low penetration of the antimicrobial inside matrix; 2) alteration in the rate of bacterial growth; and 3) horizontal transference of elements genetically mobiles that possess genes of antimicrobial resistance (5, 8) . Beside this, quorum sensing (QS) seems to be related to biofilm formation under certain growth conditions as such as medium of culture, temperature and atmosphere of incubation (4, 7).
In the study presented here we evaluated the ability of biofilm formation among P. aeruginosa isolates recovered from cystic (CF+) and non-cystic fibrosis (CF-) patients. Pseudomonas aeruginosa PAO1 (biofilm-producing) and P. aeruginosa ATCC 27853 (non-biofilm-producing) were used as controls.
Biofilm production is often associated with microbial virulence and resistance (4) . Although the mechanism is still poorly elucidated, some studies reported a great ability for biofilm production among P. aeruginosa isolates from CF+ mainly by their capacity of adaptation into cystic fibrosis lung (1, 3, 9) . Similarly to other studies, we noted that most of the isolates from CF+ were able to produce biofilm "in vitro". On the other hand, a high proportion of biofilm-producing isolates among that recovered from CF-can indicate that this characteristic is an important virulence factor that can be attributed to P. aeruginosa isolates from sputa, independently of the physiologic condition of the patient since we did not observe a statistically significant association between the presence of cystic fibrosis and biofilm production (p=0.6205). analyzed and among all of them, the biofilm production was observed in 68% (50/74) of the isolates being the most classified as weak-producing (Table 1) . Only two isolates, both from CF+, showed OD 450/630 values of 0.156 (strain 34) and 0.1986 (strain 35) and were classified as moderate-biofilmproducing (Table 1 and Figure 1 ). An important aspect of this study was that we used the microtiter assay as standard technique for evaluating of biofilm production. It is known that exist many techniques (electronic and confocal microscopy, Calgary device, flow continuous cell and others) that can be used for this aim and, for this reason, the interpretation of the results obtained from different methodologies can suffer some alterations (weak to moderate or moderate to strong, for example) (5, 10).
In conclusion, our study demonstrated that most of P.
aeruginosa isolates from cystic fibrosis have capacity to produce biofilm "in vitro". Despite of this, most of them were classified as weak biofilm-producing by the methodology applied (microtiter assay). Although the cystic fibrosis isolates possess ability and flexibility to produce biofilm our results
showed a high capacity of biofilm production "in vitro" among non-cystic fibrosis isolates as well. Further investigations including a higher number of isolates can be useful to elucidate the correlation between biofilm production and clinical condition of the patient. 
